Physician profile
Eric G Lloyd
NPI 1063606895
$2,943.48
in general payments reported to CMS, 2019-2025
28 companies · $938 in 2025
The $938 reported for 2025 was more than what 82% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $476 · 2023: $766 · 2024: $764 · 2025: $938.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,468.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,467.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $417.97 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $341.06 | 2023-2025 | |
| Abbott Laboratories | $326.39 | 2022-2025 | Freestyle Libre, Freestyle Libre 3 |
| Novartis Pharmaceuticals Corporation | $314.51 | 2022-2025 | |
| Lilly USA, LLC | $309.50 | 2022-2025 | Mounjaro, Zepbound, Trulicity |
| Phathom Pharmaceuticals, INC. | $142.98 | 2025 | Voquezna |
| Bayer Healthcare Pharmaceuticals INC. | $137.52 | 2022-2024 | |
| Dexcom, INC. | $129.01 | 2023-2025 | Dexcom G6 Transmitter |
| Glaxosmithkline, LLC. | $126.51 | 2022-2024 | Arexvy, Shingrix, Trelegy Ellipta |
| Amgen INC. | $116.12 | 2023-2025 | Repatha, Krystexxa, Otezla |
| Abbvie INC. | $89.03 | 2022-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $84.58 | 2023-2025 | Jardiance, Ofev, Synjardy |
| Sanofi-Aventis U.S. LLC | $62.61 | 2024-2025 | |
| Biohaven Pharmaceutical Holding Company LTD. | $58.36 | 2022 | |
| Astellas Pharma US INC | $43.80 | 2024 | Veozah |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $29.28 | 2022-2025 | Intellis Adaptivestim |
| Xeris Pharmaceuticals, INC. | $24.16 | 2025 | Gvoke Hypopen |
| Seqirus USA INC | $22.17 | 2024 | Fluad, Flucelvax |
| Corcept Therapeutics | $22.10 | 2025 | Korlym |
| Corium, LLC | $19.65 | 2023 | Azstarys |
| Exact Sciences Corporation | $18.80 | 2023 | Cologuard Collection Kit |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $18.40 | 2025 | Xifaxan |
| Inari Medical, INC. | $17.63 | 2023 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Takeda Pharmaceuticals U.S.A., INC. | $16.95 | 2022 | |
| Janssen Pharmaceuticals, INC | $15.26 | 2023 | Xarelto |
| Esperion Therapeutics, INC. | $14.01 | 2022 | |
| Edwards Lifesciences Corporation | $12.99 | 2022 | |
| Organon LLC | $12.13 | 2025 | Nexplanon |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Lloyd listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.